| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. (ATRA) has 3 insiders with recent SEC Form 4 filings, including 0 buys and 14 sells. ATRA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.32M | $13.97M | - | |
| CEO | 143.1K | $1.51M | - | |
| Other | 52.0K | $549.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 30,800 | $19.38 | $596,808.00 | -2.0% | |
| Mar 15, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 6,000 | $19.60 | $117,600.00 | -1.5% | |
| Mar 10, 2017 | Soffer Gad | EVP &Chief Strategy Officer | Sell | 2,500 | $20.00 | $50,000.00 | -0.9% | |
| Mar 10, 2017 | McGrath John | EVP &Chief Financial Officer | Sell | 24,000 | $20.00 | $480,000.00 | -15.9% | |
| Feb 21, 2017 | McGrath John | EVP &Chief Financial Officer | Sell | 9,000 | $15.14 | $136,260.00 | -5.6% | |
| Feb 16, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sale+OE | 4,800 | $15.56 | $74,664.00 | -0.7% | |
| Feb 16, 2017 | Gallagher Carol Giltner | Director | Sale+OE | 1,183 | $16.10 | $19,046.30 | -1.1% | |
| Feb 16, 2017 | Clark Mitchall G. | EVP &Chief R &Qa Officer | Sale+OE | 3,059 | $15.96 | $48,821.64 | -2.0% | |
| Feb 16, 2017 | Soffer Gad | EVP &Chief Strategy Officer | Sale+OE | 14,273 | $15.42 | $220,144.26 | -2.6% | |
| Feb 15, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sale+OE | 7,604 | $15.49 | $117,785.96 | -1.9% |